Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Hans‐Ulrich Herold"'
Autor:
Daniel Buergy, Florian Würschmidt, Eleni Gkika, Juliane Hörner‐Rieber, Stefan Knippen, Sabine Gerum, Panagiotis Balermpas, Christoph Henkenberens, Theresa Voglhuber, Christine Kornhuber, Steffen Barczyk, Barbara Röper, Ali Rashid, Oliver Blanck, Andrea Wittig, Hans‐Ulrich Herold, Thomas Baptist Brunner, Reinhart A. Sweeney, Klaus Henning Kahl, Ilja Frank Ciernik, Annette Ottinger, Victor Izaguirre, Florian Putz, Laila König, Michael Hoffmann, Stephanie Elisabeth Combs, Matthias Guckenberger, Judit Boda‐Heggemann
Publikováno v:
Int. J. Cancer 151, 412-421 (2022)
Optimal doses for the treatment of adrenal metastases with stereotactic radiotherapy (SBRT) are unknown. We aimed to identify dose-volume cut-points associated with decreased local recurrence rates (LRR). A multicenter database of patients with adren
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8481941d6a7e7f19238817d51a75e866
https://push-zb.helmholtz-muenchen.de/frontdoor.php?source_opus=64811
https://push-zb.helmholtz-muenchen.de/frontdoor.php?source_opus=64811
Autor:
Stefan Janssen, Andrea Wittig, Guido Hildebrandt, Eleni Gkika, Fabian Lohaus, E. Schrade, Detlef Imhoff, Lorenz Uhlmann, Peter Hass, Christoph Henkenberens, Denise Bernhardt, Hans-Ulrich Herold, Irina Sackerer, Oliver Blanck, Davide Scafa, Juliane Hörner-Rieber, Arndt-Christian Mueller, Robert Krempien, H. Kahl, Hans Th. Eich, Matthias Guckenberger, Marciana Nona Duma, Stefan Friedrich Lautenschläger, Sabine Gerum, Katrin Jurianz, Cordula Petersen
Publikováno v:
Clinical Lung Cancer. 20:e667-e677
This multicenter study aims to analyze outcome as well as early versus late patterns of recurrence following pulmonary stereotactic body radiotherapy (SBRT) for patients with oligometastatic non-small-cell lung cancer (NSCLC).This analysis included 3
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f620740f0a7d265b2490fd3f93c17bd
https://doi.org/10.1016/j.cllc.2019.06.024
https://doi.org/10.1016/j.cllc.2019.06.024
Autor:
Annette Ottinger, Michael Hoffmann, Christine Kornhuber, Andrea Wittig, Theresa Voglhuber, Juliane Hörner-Rieber, Florian Putz, Stephanie E. Combs, Stefan Knippen, Florian Würschmidt, S. Gerum, Hans Ulrich Herold, Steffen Barczyk, Oliver Blanck, Barbara Röper, Thomas Brunner, K.H. Kahl, Panagiotis Balermpas, Rainer J. Klement, Ali Rashid, Victor Izaguirre, Eleni Gkika, Matthias Guckenberger, Daniel Buergy, Ilja F. Ciernik, C. Henkenberens, Laila König, Judit Boda-Heggemann
Publikováno v:
Int. J. Cancer 149, 358-370 (2021)
To report outcome (freedom from local progression: FFLP, overall survival: OS, and toxicity) after stereotactic, palliative, or highly conformal fractionated (> 12) radiotherapy (SBRT, Pall-RT, 3DCRT/IMRT) for adrenal metastases in a retrospective mu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::927887eb65885404bc97f367617e3cbe
https://push-zb.helmholtz-muenchen.de/frontdoor.php?source_opus=61436
https://push-zb.helmholtz-muenchen.de/frontdoor.php?source_opus=61436